How to use blood-based biomarkers to diagnose Alzheimer’s disease

This episodes summarizes three papers on significant advancements and clinical recommendations for utilizing blood-based biomarkers to diagnose Alzheimer’s disease and other neurodegenerative conditions. Research highlights how testing for proteins like p-tau217, amyloid-beta, and neurofilament light chain offers a less invasive, more affordable alternative to traditional spinal taps or PET scans. New clinical practice guidelines suggest that tests meeting specific accuracy thresholds can effectively triage patients or even substitute for older diagnostic methods in specialized memory clinics. However, experts emphasize that these tools must be part of a comprehensive medical evaluation and require standardized interpretation to manage potential diagnostic errors. Ethical considerations and the need for provider training remain central to integrating these scalable technologies into routine healthcare. Ongoing efforts focus on harmonizing laboratory methods to ensure consistent results across different testing platforms and global regions.